Benzinga | Jan 19, 2021 07:09AM EST

Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium On Jan. 20

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI). The data presentation, entitled "Microbiome therapeutics to treat bacterial infections and inflammatory disease," will take place virtually at the Keystone Symposium Harnessing the Microbiome for Disease Prevention and Therapy on January 20, 2021.